J&J beats street with profits, sales

Johnson & Johnson's $15.4 billion in second-quarter revenues beat analyst forecasts as Remicade sales came on strong, partly making up for patent expirations on the antipsychotic Risperdal and the seizure med Topamax. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.